Treatment with the platelet-activating factor antagonist TCV-309 in patients with severe systemic inflammatory response syndrome: a prospective, multi-center, double-blind, randomized phase II trial

In a prospective randomized, double-blind, placebo-controlled clinical study, the safety and efficacy of the platelet-activating factor antagonist TCV-309 in the treatment of systemic inflammatory response syndrome was studied. In total 29 patients were treated with 1.0 mg/kg TCV-309 twice daily dur...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Shock (Augusta, Ga.) Ga.), 1996-05, Vol.5 (5), p.313-319
Hauptverfasser:	Froon, A M, Greve, J W, Buurman, W A, van der Linden, C J, Langemeijer, H J, Ulrich, C, Bourgeois, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Double-Blind Method Female Humans Isoquinolines - administration & dosage Male Middle Aged Platelet Activating Factor - antagonists & inhibitors Platelet Aggregation Inhibitors - administration & dosage Prospective Studies Pyridinium Compounds - administration & dosage Systemic Inflammatory Response Syndrome - drug therapy Systemic Inflammatory Response Syndrome - physiopathology Tetrahydroisoquinolines Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!